Abstract Number: 1446 • 2013 ACR/ARHP Annual Meeting
The Efficacy Of Etanercept In Combination With Methotrexate In Moderate To Severe Rheumatoid Arthritis Is Not Dependent On The Dosage Of Methotrexate
Background/Purpose: Anti-TNF therapy in combination with a synthetic DMARD such as methotrexate (MTX) has been extensively shown to be superior to MTX and anti-TNF therapy…Abstract Number: 493 • 2013 ACR/ARHP Annual Meeting
A Real-World Risk Analysis Of Biological Treatment (Adalimumab and Etanercep) In Country With High Prevalence Of Tuberculosis and Hepatitis B/C
Background/Purpose: Biologics have been widely utilized in many rheumatic diseases. Risks associated with the use of biological treatments are revealed in many published studies. Nevertheless,…Abstract Number: 195 • 2013 ACR/ARHP Annual Meeting
Major Cost Savings Associated With Reduced Biologic Dosing Frequency In Inflammatory Arthritis
Background/Purpose: Biologic agents are highly effective in Inflammatory Arthritis (IA) but are extremely expensive. A sustained reduction in biologic dosing frequency would lead to major…Abstract Number: 2821 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Selective Manipulation Of The CD28 Co-Stimulation Pathway In The Rhesus Monkey Model Of Collagen-Induced Arthritis
Background/Purpose: T-cells are important in the pathogenesis of rheumatoid arthritis (RA). T-cell activation depends on at least two signals. Next to the first signal that…Abstract Number: 2041 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women Exposed To Golimumab
Background/Purpose: Rheumatologic conditions and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing…Abstract Number: 1427 • 2013 ACR/ARHP Annual Meeting
Discovery and Characterization Of ABT-122, An Anti-TNF/IL-17 DVD-Ig™ Molecule As a Potential Therapeutic Candidate For Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a serious autoimmune disease that significantly impacts patients’ quality of life. Several approved biologic drugs targeting tumor necrosis factor (TNF)…Abstract Number: 463 • 2013 ACR/ARHP Annual Meeting
An Indirect Comparisons Analysis Between Biologic Disease Modifiers in The Treatment Of Rheumatoid Arthritis To Evaluate For Efficacy and Safety
Background/Purpose: There are primarily six groups of biologic disease modifiers (BDM) for treatment of rheumatoid arthritis (RA): tumor necrosis factor inhibitors (infliximab (IFX), etanercept (ETN),…Abstract Number: L7 • 2013 ACR/ARHP Annual Meeting
Improvement in Psoriasis Symptoms and Physical Functioning with Secukinumab Compared with Placebo and Etanercept in Subjects with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results of a Subanalysis from the Phase 3 Fixture Study
Background/Purpose: Secukinumab (SEC; AIN457), a fully human anti–IL-17A monoclonal antibody, has demonstrated efficacy in phase 3 trials for treatment of plaque psoriasis and preliminary results…Abstract Number: 2761 • 2013 ACR/ARHP Annual Meeting
Comparative Risks Of Herpes Zoster Among RA Patients Switching Biologics In The U.S. Medicare Program
Background/Purpose: Several newer biologics have been approved for treatment of rheumatoid arthritis (RA) in the United States. However, their comparative risks of herpes zoster infection…Abstract Number: 2042 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women With Rheumatologic Conditions Exposed To Infliximab
Background/Purpose: RA, AS, and PsA are approved indications for infliximab (IFX). In the US, IFX is a pregnancy Category B drug. For RA and some…Abstract Number: 1414 • 2013 ACR/ARHP Annual Meeting
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Prior Treatment With Methotrexate
Background/Purpose: The safety and efficacy of subcutaneous golimumab (GLM)+/-MTX has been evaluated through 2yrs in a phase 3 trial (GO-FORWARD) of pts with active rheumatoid…Abstract Number: 477 • 2013 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes In Patients With Active Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) has a substantial impact on patient quality of life (QOL), physical functioning, and other outcomes important to patients. This subanalysis of…Abstract Number: 2768 • 2013 ACR/ARHP Annual Meeting
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: 2-Year Results Of a Phase 3 Trial Of Intravenous Golimumab
Background/Purpose: To evaluate long-term clinical/radiographic efficacy of IV GLM 2mg/kg+MTX in active RA despite MTX through wk112. Methods: 592 pts with active RA (≥6/66 SJC,…Abstract Number: 2043 • 2013 ACR/ARHP Annual Meeting
Perinatal Exposure To Traditional and Biologic Disease Modifying Antirheumatic Drugs In Rheumatic Diseases: A Systematic Review Of Congenital Outcomes
Background/Purpose: Despite the high incidence of rheumatic diseases during reproductive years, little is known about the perinatal impact of traditional and biologic disease modifying antirheumatic…Abstract Number: 1416 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Golimumab In Chinese Patients With Active Rheumatoid Arthritis Despite MTX Therapy: Results From a Randomized, Placebo-Controlled, Phase 3 Trial
Background/Purpose: Assess safety and efficacy of GLM+MTX over 1yr in a multicenter, randomized, placebo (PBO)-controlled study of Chinese pts with active RA despite MTX therapy.…
ACR Meeting Abstracts